Answers are grounded in this paper and cite their sources.
Background Extensive glioblastoma infiltration justifies a 15-mm margin around the gross tumor volume (GTV) to define the radiotherapy clinical target volume (CTV). Amide proton transfer (APT)-weighted imaging could enable visualization of tumor infiltration, allowing more accurate GTV delineation. We quantified the impact of integrating APT-weighted imaging into GTV delineation of glioblastoma and compared two APT-weighted quantification methods—magnetization transfer ratio asymmetry (MTR asym ) and Lorentzian difference (LD) analysis—for target delineation. Methods Nine glioblastoma patients underwent an extended imaging protocol prior to radiotherapy, yielding APT-weighted MTR asym and LD maps. From both maps, biological tumor volumes were generated (BTV MTRasym and BTV LD ) and added to the conventional GTV to generate biological GTVs (GTV bio,MTRasym and GTV bio,LD ). Wilcoxon signed-rank tests were performed for comparisons. Results The GTV bio,MTRasym and GTV bio,LD were significantly larger than the conventional GTV ( p ≤ 0.022), with a median volume increase of 9.3% and 2.1%, respectively. The GTV bio,MTRasym and GTV bio,LD were significantly smaller than the CTV ( p = 0.004), with a median volume reduction of 72.1% and 70.9%, respectively. There was no significant volume difference between the BTV MTRasym and BTV LD ( p = 0.074). In three patients, BTV MTRasym delineation was affected by elevated signals at the brain periphery due to residual motion artifacts; this elevation was absent on the APT-weighted LD maps. Conclusion Larger biological GTVs compared to the conventional GTV highlight the potential of APT-weighted imaging for radiotherapy target delineation of glioblastoma. APT-weighted LD mapping may be advantageous for target delineation as it may be more robust against motion artifacts. Relevance statement The introduction of APT-weighted imaging may, ultimately, enhance visualization of tumor infiltration and eliminate the need for the substantial 15-mm safety margin for target delineation of glioblastoma. This could reduce the risk of radiation toxicity while still effectively irradiating the tumor. Trial registration NCT05970757 (ClinicalTrials.gov). Key Points Integration of APT-weighted imaging into target delineation for radiotherapy is feasible. The integration of APT-weighted imaging yields larger GTVs in glioblastoma. APT-weighted LD mapping may be more robust against motion artifacts than APT-weighted MTR asym .
No takes yet. Share an insight, caveat, or question.
Tang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: